Key regions: Europe, India, Canada, Italy, South Korea
Bronchodilator drugs are widely used in Brunei Darussalam to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs in the country has been developing in recent years due to various factors.
Customer preferences: Patients in Brunei Darussalam prefer bronchodilator drugs that are effective and affordable. They are also increasingly seeking drugs that have fewer side effects and are easier to use, such as inhalers.
Trends in the market: One trend in the bronchodilator drugs market in Brunei Darussalam is the increasing use of combination drugs. These drugs combine two or more bronchodilators or a bronchodilator with an anti-inflammatory drug. Combination drugs are more effective in treating respiratory diseases and are more convenient for patients as they only need to take one medication instead of multiple.Another trend is the growing availability of generic bronchodilator drugs. Generic drugs are cheaper than brand-name drugs, making them more accessible to patients. This has led to increased competition in the market, which has driven down prices.
Local special circumstances: Brunei Darussalam has a small population and a high standard of living, which means that the healthcare system is well-funded and efficient. The government provides free healthcare to citizens and residents, which has increased access to bronchodilator drugs.
Underlying macroeconomic factors: The economy of Brunei Darussalam is heavily dependent on oil and gas exports. However, the government has been diversifying the economy in recent years, which has led to increased investment in healthcare. This has resulted in better healthcare infrastructure and increased access to medication, including bronchodilator drugs.In conclusion, the bronchodilator drugs market in Brunei Darussalam is developing due to the increasing use of combination drugs, the growing availability of generic drugs, the efficient healthcare system, and the government's investment in healthcare infrastructure. Patients in the country prefer effective and affordable drugs with fewer side effects, and the government's commitment to providing free healthcare has increased access to medication.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
